Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Only the indication and mechanism-of-action-related COX/prostaglandin statements appear supported by the provided label excerpts. Most other claims (e.g., generic availability/patents/biosimilar concepts, common side effects and specific severity claims like corneal ulceration/perforation, and multiple non-label administrative/market-explanation statements) are not supported or are not verifiable from the supplied prescribing information excerpts, leading to low overall alignment.
Category Scores
Accurate Statements
Bromfenac is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Label 1 INDICATIONS AND USAGE: “indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.”
Bromfenac is used post-operatively after cataract surgery to reduce ocular pain and postoperative inflammation.
Label 1 INDICATIONS AND USAGE and 14.1 Clinical Studies (postoperative inflammation and reduction of ocular pain endpoint in cataract surgery).
Apply one drop to the affected eye once daily beginning 1 day prior to cataract surgery and continue through the first 14 days of the postoperative period.
Label 2.1 Recommended Dosage: “once daily beginning 1 day prior to cataract surgery… through the first 14 days of the postoperative period.”
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) and blocks prostaglandin synthesis via inhibiting cyclooxygenase (COX) 1 and 2.
Label 12.1 Mechanism of Action: “block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2.”
COX enzymes are responsible for prostaglandin production and bromfenac reduces inflammation/pain by blocking prostaglandin synthesis (COX inhibition).
Label 12.1 Mechanism of Action: “inhibiting cyclooxygenase (COX) 1 and 2” leading to “block prostaglandin synthesis” and “has anti-inflammatory activity.”
Unsupported Statements
Bromfenac is an NSAID used to treat pain and inflammation.
Only anti-inflammatory activity and postoperative ocular pain/inflammation after cataract surgery are supported in the provided label excerpts; the broader statement is not explicitly supported as a general indication outside the cataract postoperative context.
Generic bromfenac is available in generic forms.
Not supported in the supplied prescribing information excerpts (label does not discuss market/generic availability).
The term "biosimilar" does not apply to bromfenac; instead, generic versions are developed.
Not addressed in the provided prescribing information excerpts.
Multiple pharmaceutical companies produce generic versions of bromfenac.
Not addressed in the provided prescribing information excerpts.
Generic versions of bromfenac become available after expiration of patents held by the original drug developer.
Not addressed in the provided prescribing information excerpts.
Patent expiry information can be found through resources like DrugPatentWatch.com.
Not addressed in the provided prescribing information excerpts.
Patent protection grants a period of market exclusivity for drug manufacturers.
Not addressed in the provided prescribing information excerpts.
Detailed information about bromfenac's patent landscape, including expiry dates and ongoing litigation, is available on specialized patent tracking websites such as DrugPatentWatch.com.
Not addressed in the provided prescribing information excerpts.
The cost of generic bromfenac can vary significantly depending on the pharmacy, insurance coverage, and dosage.
Not addressed in the provided prescribing information excerpts.
Generally, generic medications are substantially less expensive than brand-name counterparts.
Not addressed in the provided prescribing information excerpts.
Common side effects of bromfenac include corneal issues.
The label excerpt lists common adverse reactions after cataract surgery as anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred; “corneal issues” are not stated in the provided adverse reaction excerpt.
More serious side effects can include corneal ulceration.
The provided label excerpt does not mention corneal ulceration.
More serious side effects can include corneal perforation.
The provided label excerpt does not mention corneal perforation.
Patients should report vision changes or severe eye irritation to their healthcare provider immediately during bromfenac use.
The provided label excerpt includes adverse reactions reporting rates but does not include this specific patient counseling instruction or thresholds (“immediately”, “severe eye irritation”).
Corticosteroid eye drops are also used to manage post-operative inflammation and pain after eye surgery.
Not addressed in the provided prescribing information excerpts.
Other NSAIDs are also used to manage post-operative inflammation and pain after eye surgery.
Not addressed in the provided prescribing information excerpts.
Bromfenac is a small molecule drug, not a biologic.
The provided prescribing information excerpt does not explicitly discuss small-molecule vs biologic categorization.
Common side effects of bromfenac include blurred vision.
This is supported as “vision blurred” in the label excerpt; however, without explicit mapping to “common side effects” wording beyond “most commonly reported adverse reactions,” the statement is only partially supported. (Included here as unsupported due to lack of exact label phrasing for “side effects”/“common side effects” beyond the adverse reaction list.)
Common side effects of bromfenac include eye pain.
This is supported as “eye pain” among the most commonly reported adverse reactions in the label excerpt; however, similar to “common side effects” phrasing, the label uses “most commonly reported adverse reactions.” (Included here as unsupported due to mismatch in framing.)
Contradictions
Low
AI Statement
Generic versions of bromfenac become available after expiration of patents held by the original drug developer.
Label Reference
Important Omissions
Complete safety-relevant label content for warnings/precautions beyond the provided excerpt (e.g., detailed warnings, contraindications list confirmation, drug interactions, monitoring instructions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or unverified claims about specific serious corneal adverse events (ulceration/perforation) and specific patient-reporting instructions could mislead users about risk severity and escalation steps; however, no direct contradictions to the provided label excerpts were identified for the cataract postoperative indication/dosing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Many non-label claims (generic/patent/biosimilar/price information and additional adverse event specifics like corneal ulceration/perforation) are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to label-supported content for bromfenac ophthalmic solution 0.07%: indication and specific dosing regimen after cataract surgery; mechanism of action (COX 1/2 inhibition and prostaglandin synthesis blockade). For adverse reactions, restrict to the specific adverse reactions listed in the label excerpt (e.g., anterior chamber inflammation, foreign body sensation, eye pain, photophobia, vision blurred) unless the full label provides corneal ulceration/perforation details. Remove or clearly separate non-label market/patent/cost assertions from label-based statements.